Literature DB >> 17120733

The value of p63 and CK5/6 expression in the differential diagnosis of ductal lesions of breast.

Yanping Ding1, Qiurong Ruan.   

Abstract

In order to explore the value of p63, smoothmuscle actin (alpha-SMA) and cytokeratin 5/6 (CK5/6) in the differential diagnosis of ductal lesions of breast, 88 tissue specimens of ductal lesions of breast were collected and examined histologically by HE staining. By using immunohistochemistry, the expression of p63, alpha-SMA and CK5/6 was detected. The results showed that in 38 cases of benign breast lesions, the proliferating cells were all positive for p63 and alpha-SMA. In 19 cases of ductal carcinoma in situ (DCIS) and 7 cases of intraductal papillary carcinoma, alpha-SMA positive cells formed a layer of continuous embroider-shaped structure and the p63 positive cells formed a layer of evenly separated embroider-shaped structure around the ducts. There was no cross-reaction between p63 and interstitial myofibroblasts and vascular smooth muscle cells. In 38 cases of benign breast lesions, the positive rate of CK5/6 expression was 100%. In 5 cases of atypical ductal hyperplasia, there were few positive cells in the ducts. In 19 cases of CDIS, no tumor cells expressed CK5/6. In 19 cases of invasive ductal carcinoma, almost no CK5/6 was detectable. It was suggested that p63 could serve as a novel specific marker for the identification of breast myoepithelial cells. CK5/6 is of value in differentiating ductal proliferation of varying degrees, especially in the differentiation between cancerous and non-cancerous changes. Simultaneous detection of p63, CK5/6 and alpha-SMA can help increase the diagnostic accuracy of breast diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17120733     DOI: 10.1007/s11596-006-0406-x

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  7 in total

Review 1.  Taking advantage of basic research: p63 is a reliable myoepithelial and stem cell marker.

Authors:  Jorge S Reis-Filho; Fernando C Schmitt
Journal:  Adv Anat Pathol       Date:  2002-09       Impact factor: 3.875

Review 2.  The usefulness of p63 as a marker of breast myoepithelial cells.

Authors:  Anna Batistatou; Dimitrios Stefanou; Evdokia Arkoumani; Niki J Agnantis
Journal:  In Vivo       Date:  2003 Nov-Dec       Impact factor: 2.155

3.  Observer variability in the histopathological reporting of core biopsies of papillary breast lesions is reduced by the use of immunohistochemistry for CK5/6, calponin and p63.

Authors:  A Douglas-Jones; V Shah; J Morgan; N Dallimore; M Rashid
Journal:  Histopathology       Date:  2005-08       Impact factor: 5.087

4.  p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast.

Authors:  M Barbareschi; L Pecciarini; M G Cangi; E Macrì; A Rizzo; G Viale; C Doglioni
Journal:  Am J Surg Pathol       Date:  2001-08       Impact factor: 6.394

5.  Availability of CD10 immunohistochemistry as a marker of breast myoepithelial cells on paraffin sections.

Authors:  Suzuko Moritani; Ryoji Kushima; Hiroyuki Sugihara; Masamichi Bamba; Tadao K Kobayashi; Takanori Hattori
Journal:  Mod Pathol       Date:  2002-04       Impact factor: 7.842

6.  Value of cytokeratin 5/6 immunostaining using D5/16 B4 antibody in the spectrum of proliferative intraepithelial lesions of the breast. A comparative study with 34betaE12 antibody.

Authors:  Magali Lacroix-Triki; Eliane Mery; Jean-Jacques Voigt; Luc Istier; Philippe Rochaix
Journal:  Virchows Arch       Date:  2003-04-24       Impact factor: 4.064

7.  Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain.

Authors:  Robert W Werling; Harry Hwang; Hadi Yaziji; Allen M Gown
Journal:  Am J Surg Pathol       Date:  2003-01       Impact factor: 6.394

  7 in total
  1 in total

1.  Immunostaining of ∆Np63 (using the p40 antibody) is equal to that of p63 and CK5/6 in high-grade ductal carcinoma in situ of the breast.

Authors:  Verena Sailer; Christine Lüders; Walther Kuhn; Volker Pelzer; Glen Kristiansen
Journal:  Virchows Arch       Date:  2015-04-08       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.